and different studies of prognosis have yielded widely differing results (Hawkins, 1993) . We have selected four putative biochemical indices of prognosis and evaluated them in a prospective study. The putative markers chosen were the oestrogen receptor (ER), the epidermal growth factor receptor (EGFR), cathepsin D (cath D) and cyclic AMP-binding protein(s) (c-AMP-b).
Despite the existence of a large number of molecules which have been reported to be of value in gauging prognosis, it remains difficult to predict outcome accurately in 'early' (operable) breast cancer (Osborne, 1992) and different studies of prognosis have yielded widely differing results (Hawkins, 1993) . We have selected four putative biochemical indices of prognosis and evaluated them in a prospective study. The putative markers chosen were the oestrogen receptor (ER), the epidermal growth factor receptor (EGFR), cathepsin D (cath D) and cyclic AMP-binding protein(s) (c-AMP-b).
The oestrogen receptor, a nuclear protein (Mr 66 kDa) has been shown to relate to both endocrine sensitivity (Jensen, 1975) and prognosis in multiple studies, including our own previous work (Humeniuk et al., 1982; Hawkins et al., 1987a Hawkins et al., , 1991 , although some consider that it is only of prognostic significance in the early years after treatment (e.g. Saez et al., 1983) . The receptor for epidermal growth factor is a membrane protein (Mr 180 kDa), which has been reported to be a sign of bad prognosis, again in multiple studies (Sainsbury et al., 1987; Gasparini et al., 1992) . The proteolytic enzyme, cathepsin D (Mr 52 kDa), has been suggested to be involved in metastasis formation and reported in several studies also to be a sign of bad prognosis when present in high levels (for a review see Rochefort, 1990) . Lastly, work in our own laboratories and elsewhere has demonstrated that high levels of cyclic AMP-binding protein(s), the regulatory subunits of the enzyme protein kinase A, represent another sign of poor prognosis, in both retrospective (Miller et al., 1990) and prospective (Miller et al., 1993) studies.
In this paper, we report our findings for these markers and for patient outcome MO) , 215 were included in this study. Excluded were patients with previous malignancies (breast or other sites), bilateral disease or purely non-invasive cancers (Tis). Also excluded were cases where the specimen contained inadequate tumour (< 10% tumour in a section cut from the face of the specimen used for biochemistry) or where the specimen was too small to permit all four biochemical assays to be performed. Of the cases excluded for these reasons, the major group was that of the smaller tumours (TI, approximately one-third of all the cases).
The histopathology of the 215 cases was reviewed retrospectively by one of us (MMcI) from both the section cut from the tissue block used for biochemistry and the original pathology report. Pathological tumour size, histopathological grade (Bloom and Richardson, 1957) and histopathological tumour type were recorded. For analytical purposes, the tumour type was categorised in order of anticipated prognostic significance (based on Dixon et al., Fisher et al., 1993) as (1) clearance; (3) wedge biopsy/node biopsy before primary systemic therapy (chemo-or endocrine) followed by mastectomy 4-6 months later (tumours >4 cm). Most patients also received adjuvant therapy after definitive surgery, either endocrine therapy (e.g. tamoxifen) or chemotherapy (CMF), depending on factors such as node status and oestrogen receptor levels. Among the 215 patients, eight were treated by primary systemic therapy (seven in a randomised trial, one elderly patient received preoperative tamoxifen). Of the remainder, all postmenopausal patients received adjuvant tamoxifen therapy post-operatively, except for four patients, two of whom received chemotherapy. Premenopausal, node-negative patients were all given tamoxifen or no adjuvant therapy, apart from three patients (all with low ER levels), who received chemotherapy as part of a randomised trial. Premenopausal, node-positive patients received adjuvant chemotherapy or underwent ovarian ablation, apart from one patient (with a high ER level), who received tamoxifen.
Patients were thus categorised as receiving: (1) no adjuvant therapy (n= 7); (2) adjuvant chemotherapy (n= 33); (3) adjuvant endocrine therapy (n = 167); (4) primary chemotherapy (n = 4); or (5) primary endocrine therapy (n = 4). Those who had conservation surgery received post-operative radiotherapy.
For the purpose of data analysis, patients were classified as: (1) premenopausal (last period < 12 months before surgery and those under 50 years, who had had a previous hysterectomy without bilateral oophorectomy); (2) postmenopausal (last period > 12 months before surgery, those of any age who had had a previous bilateral oophorectomy and those of 50 years or more who had had a hysterectomy without oophorectomy).
The patients were followed up at 4-6 monthly intervals and had annual mammography carried out. Those who received primary systemic therapy were seen more frequently before their definitive surgery but, thereafter, the follow-up was as for those treated by initial surgery.
During follow-up (24.8-46.5 months, median 36.2 months), 55 patients had a recurrence (18 locoregional only) and 35 died (30 from breast cancer). An initial preliminary analysis was also performed after a median follow-up of only 16.5 months (range 1-25 months), but the results are not detailed here because: (1) that follow-up was very short; and (2) the findings were virtually identical with those presented here after 3 years.
Determination of oestrogen receptor activity Oestrogen receptor activity was determined by enzyme immunoassay (ER-EIA) using the Abbott kit, according to the manufacturer's instructions. In brief, tissue cytosols were prepared by homogenisation in Tris-glycerol-monothioglycerol buffer (Hawkins et al., 1981) and centrifugation at 105 000 x g. An aliquot of cytosol was assayed for protein by the method of Bradford (1976) (see below) so that the cytosol could be diluted to 1-2 mg protein ml-'. A 100 ,l sample of each cytosol and the Abbott quality control were pipetted with diluent into separate wells of a microtitre plate alongside 200 ,l receptor standards (0, 5, 25, 100 and 250 fmol ml-'). A glass bead, coated with the first anti-ER antibody, was added to each well, left to bind overnight (18 h) at 4°C before aspiration, washing and incubation with a second anti-ER antibody, conjugated to peroxidase, for 1 h at 37°C. After reaspiration and washing, the beads were incubated in 300 pl o-phenylenediamine solution for 30 min at 30°C, the reaction was terminated by the addition of 1.0 ml sulphuric acid solution (1 N) and the yellow colour was read at 492 nm. From the resulting standard curve, the values in the unknowns were calculated by interpolation, corrected for the dilution and expressed as fmol mg-' protein. Three additional quality control samples (two uterine tissues and one pool of breast cancer cytosol) were processed with each assay.
Although initially (Hawkins et al., 1987b) By this assay, the ER concentrations found in 'normal breast' (taken from patients with either no malignancy or from an area remote from the tumour in a patient with cancer, this being confirmed by histological examination) were 9 fmol mg-' protein (median; range 2-28, n = 8), in fibroadenomata 31 (median; range 6-80, n = 10) and in more complex benign lesions 47 (median; range 6-102, n=8).
Determination of EGFR EGFR was determined on the 'membranes' pellet remaining after high-speed centrifugation of the homogenate used for ER assay, by modification of a method described previously (Hawkins et al., 1991 (300 nM) of non-radioactive EGF. The tubes were mixed and incubated (total volume 0.4 ml) for 90 min at 26°C before separation of free and bound EGF by the addition of 0.5 ml IgG solution (0.5% w/v) and 1.0 ml of polyethylene glycol (25% v/v), incubation on ice for 15 min and centrifugation. An additional 100 pl aliquot of membranes was assayed for proteins (Bradford, 1976; see below) .
In our experience, this SSD method measures only highaffinity sites by comparison with the multidose saturation method we used previously (Hawkins et al., 1991) [correlation between the assays: 1 (SSD) = 1.15 x (Scatchard) + 0.72 fmol mg-protein, Spearman's r = 0.70, n =24 tissues]. In our hands, the use of higher concentrations of [251I]EGF (1 nM) in such an assay (Nicholson et al., 1988) yielded measurements of a mixture of high-and some low-affinity sites.
Portions of human uterine and rat liver membranes (stored in liquid nitrogen) were also assayed with each batch of samples as quality controls. Water blanks (n = 3) were processed with each assay and the mean value was 0.18 fmol per tube for n = 61 assays. This yields a theoretical sensitivity of 1.43 fmol mg-' membrane protein, assuming a typical protein content of 0.3 mg per tube, using the method of Brown et al. (1957) .
Using this assay, the mean EGFR concentrations found in normal breast (n = 8), fibroadenomata (n= 10) and more complex benign lesions (n = 8) were 1.96 (range 0-5.11), 1.79 (range 0-4.70) and 2.12 (range 0.48-3.32) fmol mg-1 membrane protein respectively.
Determination of cathepsin D The cytosol remaining after the ER assay was frozen at -200C for 1 -2 weeks and kept for the assay of cathepsin D.
The thawed cytosol was assayed using the CIS kit, according to the manufacturer's instructions.
The CIS kit employs the use of two monoclonal antibodies prepared against sterically remote antigenic sites on the cathepsin D molecule. The first antibody (Ab,) is coated on the ELSA tube and the second is radiolabelled with ['1251] (Ab). Portions of uterine cytosol were also assayed with each batch of samples, as quality controls.
Using this assay, the average cathepsin D concentrations found in normal breast (n = 8), fibroadenomata (n =10) and more complex benign lesions (n = 8) were 9 (range 3-14), 14 (range 8 -20) and 30 (range 9 -59) pmol mg-' cytosolic protein respectively.
Determination of cyclic AMP-binding protein(s)
A portion of the tumour biopsy was homogenised and assayed as described previously by Miller et al. (1985) . In brief, a cytosol was prepared at 0°C by homogenising tumour in 20 mM Tris buffer (w/v 1: 10) and centrifuging at 105 000 x g for 1 h at 4°C. The resulting cytosol (50 dl) was incubated with 5'8' [3H] cyclic AMP (100 1l 25 nM) ± varying concentrations of non-radioactive cyclic AMP for 3 h at room temperature. The protein-bound fraction of cyclic AMP was separated from the free fraction by filtration through a Millipore filter, dried and counted in a micellar scintillator. The results were analysed by Scatchard (1949) Five quality control samples were processed in each assay and, where the mean value deviated by > 10% from the expected, the assay was repeated. Statistical evaluation of results The inter-relationships between variables were examined by calculating Spearman's rank correlation coefficient and the relationship of each putative factor to prognosis (disease-free interval or death) was examined by Cox's proportional hazards regression model in univariate and multivariate In these analyses, a logarithmic transformation was applied to variables with noticeably skewed distributions. In addition, for each putative biochemical factor, the results were divided into quartiles according to their concentration in the tumour, and curves to indicate the probability of staying disease-free or of overall survival were drawn using Kaplan-Meier estimates. Such curves were also drawn for nodal status (two categories), tumour grade (three categories) and clinical tumour size (quartiles).
Results
Incidence of detectable activity of the biochemical markers Using arbitrary 'cut-offs', ER activity was detected in 87% Inter-relationships between the markers and other variables When the levels of pairs of biochemical markers were examined, it was found that there were correlations between the concentrations of cathepsin D and cyclic AMP-binding (Spearman's r = + 0.32), cyclic AMP-binding and ER (Spearman's r = + 0.14) and an inverse correlation between ER and EGFR activities (Spearman's r = -0.26). These correlations are illustrated in Figure 1 and summarised along with those for other variables examined in Table I .
The inter-relationships between all the 18 variables studied is shown in the form of a correlation matrix (Table I) in which the (above) correlations between the biochemical markers are emphasised in bold type.
Although there are too many associations between the 18 variables studied for detailed comment, it is instructive to note some of these findings. Many of these associations would be expected; thus, age related to menstrual status, pathological tumour size to clinical size, node status to tumour size (clinical/ pathological), and the choices of systemic therapy, radiotherapy and type of surgery are closely inter-related, with the latter two related to tumour stage, tumour size (clinical/ pathological) and node status, and the former to age and menstrual status. Equally, the soluble protein content (SPG) of a tumour extract relates strongly to the protein content of the membranes (MPG), which is prepared from the same tumour, but both relate strongly (r>0.4, P<,0.0001) to the tumour grade. Tumour grade related significantly to many features: patient's age, tumour stage, clinical or pathological tumour size, node status, tumour type, the levels of all of the four biochemical markers, type of systemic therapy and to the weight of tissue (TW) available for biochemical analysis. The strong association between the latter and tumour stage, tumour size (clinical/pathological) and tumour grade is expected, since the larger tumours were more likely to yield a larger tumour sample for biochemical analysis. These multiple interassociations highlight the need for a multivariate analysis in determining key prognostic factors, as demonstrated below. Cath D Figure 1 The inter-relationships between the four biochemical markers studied in 215 patients with operable breast cancer. The Spearman rank correlation coefficients were -0.26 (P=0.001) for log ER vs log EGFR; + 0.14 (P= 0.036) for c-AMP-b vs log ER; and +0.32 (P=0.0001) for c-AMP-b vs cath D. 2b), only ER measurements showed a clear relationship to risk of recurrence or survival: patients with ER concentrations in excess of 164 fmol mg-I protein (group 4) had a very good prognosis, those with ER< 11 fmol mg-I protein (group 1) had a very poor prognosis and those with intermediate levels (groups 2 and 3) had an intermediate prognosis (Figure 2a and b (Table V) . For risk of local recurrence, however, only tumour grade and ER concentration appeared important (Table IV) .
By multivariate analysis, ER concentration, node status and tumour grade related to risk of total recurrences or distant metastases and for the latter, clinical tumour size also proved to be of independent prognostic value, although at a less significant level (P=0.032). Only ER concentration and node status related to risk of death, but for local recurrence, tumour grade alone was of prognostic value.
The relative importance of the four key factors found to be of prognostic significance, examined simultaneously (compare the above stepwise statistical procedure), is shown in Time ( node-negative. 1987a, 1991) , it was evident that ER measurements were of prognostic value and, thus, while it seemed likely that ER might be of value, it was hoped to detect other markers, which would be of greater, additional benefit.
Of the markers studied, cathepsin D and cyclic AMP binding were inter-related. To our knowledge, this relationship has not been reported previously; its significance is uncertain. Whereas cyclic AMP-binding proteins are found in both cytoplasm and nucleus of tumour and other cells (ChoChung et al., 1978) , cathepsin D is a lysosomal enzyme of both tumour cells and macrophages (Henry et al., 1990; O'Donoghue et al., 1992; Stonelake et al., 1994) . Cyclic AMP-binding has also been detected in macrophages (Yamamoto et al., 1987) and it may be that the interrelationship between cathepsin D and cyclic AMP-finding relates to this. A weaker association was found between cyclic AMP-binding protein(s) and ER concentration, and this might simply reflect the fact that more cellular tumour specimens yield both more ER (when positive) and more cyclic AMP-binding protein(s). As has been shown previously in many other studies including our own, there was a significant inverse relationship between ER and EGFR.
After a median follow-up of 3 years, for risk of either any recurrence or death, ER concentration, node status and tumour grade remained the only significant independent factors among those examined. For It may be that similar considerations apply to cyclic AMPbinding proteins, i.e. that these, too, being found in both tumour cells and macrophages (Yamamoto et al., 1987) , may reflect the degree of inflammation in the tumour, rendering high levels of these proteins a sign of poor prognosis. In a previous, retrospective study (Miller et al., 1990) , we have found that patients with high levels of cyclic AMP binding had a very short disease-free survival, this finding being confirmed in a second, prospective study (Miller et al., 1993) . Careful comparison of these previous studies with the present work shows some changes over the years during which the studies were conducted: 1979 conducted: -84 (Miller et al., 1990 1984-87 (Miller et al., 1993); and 1990-91 (present work) . There have been changes in (1) the proportion of patients available for study from the whole population attending our Breast Clinic (12%, 15% and 33% respectively in the references Miller et al., 1990; Miller et al., 1993 and the present work); (2) the proportion of patients studied who had high levels (>8000 fmol mg-' protein) of cyclic AMP-binding in their tumours (12%, 9% and 3% respectively); and (3) the proportion of patients studied who received adjuvant or primary endocrine therapy (40%, 67% and 80% respectively). Thus, the most likely explanations for the differences between the present and earlier studies are that: (1) propose to update our study after further follow-up. The present study found no evidence that EGFR measurements offer prognostic information additional to that provided by ER concentration, node status and tumour grade. These findings are also in line with our previous study (Hawkins et al., 1991) and the results of multivariate analyses by Dutch workers (Koenders et al., 1993; Foekens et al., 1989) and may perhaps relate to factors other than the four listed above. In the present study, in order to be able to include as many tumours (irrespective of size) as possible, we changed our method for EGFR assay from a multiple-dose one with Scatchard analysis (Hawkins et al., 1991) to a single saturating-dose assay. Neither method, in our experience, is ideal, and concern has been expressed over the methodology of this assay (Koenders et al., 1992) . However, two other considerations may be of greater significance, as discussed previously (Hawkins, 1993) . Firstly, there is a strong inverse relationship between ER and EGFR measurements and, where the former are satisfactory, they may enter the Cox statistical model first and eliminate a contribution from the latter. Secondly, there appears to be no clear difference between EGFR levels in benign and malignant breast tissues (compare EGFR levels in benign tissues 0-5.11 fmol mg-' membrane protein, n = 18, and malignant tissues which, with the exception of three tumours, were all in the range 0-6.43 fmol mg-' membrane protein, n = 215; see Methods section and Barker et al., 1989; Dittadi et al., 1993) , rendering more significant the possible contribution of any benign material homogenised in the 'tumour' specimen (compare ER levels in benign tissues 2-102 fmol mg-' protein, n = 18, and malignant tissues 0-1511 fmol mg-' protein, n = 2600, unpublished observations.).
In summary, we have shown that patients with operable breast cancer are at increased risk of recurrence within 1 -3 years when ER-negative and/or node-positive and/or of low tumour grade; this recurrence being most likely to be at a distant site.
It is concluded that in the early follow-up period, ER concentration is of perhaps greater prognostic significance than is generally appreciated, especially when measured with careful quality control of both assay and tumour specimen; other biochemical factors of larger/additional prognostic significance remain to be established.
